{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:28:36Z","timestamp":1789766916392,"version":"4.0.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:p>\n            Spironolactone, a steroidal mineralocorticoid receptor antagonist, is recommended as add-on therapy for treatment-resistant\/uncontrolled hypertension. However, caution is advised in patients with advanced chronic kidney disease (CKD) due to an increased risk for hyperkalemia. KBP-5074 is a nonsteroidal mineralocorticoid receptor antagonist under investigation for the treatment of treatment-resistant and uncontrolled hypertension in patients with moderate-to-severe CKD. BLOCK-CKD is a phase 2, international, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of KBP-5074, on top of current therapy, in patients with stage 3B\/4 CKD (estimated glomerular filtration rate \u226515 and \u226444 mL\/[min\u00b71.73 m\n            <jats:sup>2<\/jats:sup>\n            ]) and resistant hypertension (trough cuff seated systolic blood pressure \u2265140 mm\u2009Hg, despite treatment with maximally tolerated doses of 2 or more antihypertensive medicines with complementary mechanisms). Patients (n=240) will be randomized 1:1:1 to once-daily treatment with KBP-5074 0.25 mg, KBP-5074 0.5 mg, or placebo, stratified by estimated glomerular filtration rate (\u226530 versus &lt;30 mL\/[min\u00b71.73 m\n            <jats:sup>2<\/jats:sup>\n            ]) and systolic blood pressure (\u2265160 versus &lt;160 mm\u2009Hg). Approximately 30% of enrolled patients should have an estimated glomerular filtration rate of 15 to 29 mL\/(min\u00b71.73 m\n            <jats:sup>2<\/jats:sup>\n            ). The primary efficacy analysis is the change in trough cuff seated systolic blood pressure from baseline to day 84 for the KBP-5074 doses compared with placebo. Changes in urinary albumin-creatinine ratio will be assessed along with changes in serum potassium\/incidence of hyperkalemia and changes in estimated glomerular filtration rate and serum creatinine. BLOCK-CKD will determine whether the addition of KBP-5074 will effectively lower blood pressure without an increased risk of hyperkalemia in patients who are not candidates for steroidal mineralocorticoid receptor antagonists due to advanced CKD.\n          <\/jats:p>\n          <jats:sec>\n            <jats:title>Registration\u2014<\/jats:title>\n            <jats:p>\n              URL:\n              <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrials.gov\">http:\/\/www.clinicaltrials.gov<\/jats:ext-link>\n              . Unique identifier: NCT 03574363.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/hypertensionaha.120.15199","type":"journal-article","created":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T18:04:49Z","timestamp":1591812289000},"page":"144-149","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":44,"title":["Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease"],"prefix":"10.1161","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1183-1267","authenticated-orcid":false,"given":"George","family":"Bakris","sequence":"first","affiliation":[{"name":"From the Department of Medicine, American Heart Association Comprehensive Hypertension Center, The University of Chicago Medicine, IL (G.B.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. Fred","family":"Yang","sequence":"additional","affiliation":[{"name":"KBP Biosciences, Princeton, NJ (Y.F.Y.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Michigan School of Medicine, Ann Arbor (B.P.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_4_2_2","unstructured":"National Institute of Health Institute of Diabetes Digestive and Kidney Disease. United States Renal Data System. 2019 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases Bethesda MD: 2019. Available at: https:\/\/usrds.org\/2019\/view\/Default.aspx. Accessed March 26 2019."},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000084"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-14-132"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2009.09.014"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041031"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f5680"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.7326\/M14-0488"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0910975"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000065"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00257-3"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2014.04.008"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfx312"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7110459"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1159\/000479802"},{"key":"e_1_3_4_16_2","volume-title":"Inspra [packet insert]","year":"2018","unstructured":"Inspra [packet insert]. New York, NY: Pfizer; May 2018."},{"key":"e_1_3_4_17_2","volume-title":"Aldactone [package insert]","year":"2018","unstructured":"Aldactone [package insert]. New York, NY: Pfizer; April 2018."},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.10081"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht187"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01073-5"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000000366"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.117.10360"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.657957"},{"key":"e_1_3_4_24_2","article-title":"Pharmacological profile of KBP-5074, a novel non- steroidal mineralocorticoid receptor antagonist for the treatment of cardiorenal diseases.","volume":"3","author":"Chow CP","year":"2017","unstructured":"Chow, CP, Liu, JR, Tan, XJ, Huang, ZH. Pharmacological profile of KBP-5074, a novel non- steroidal mineralocorticoid receptor antagonist for the treatment of cardiorenal diseases. J Drug Res Dev. 2017;3:doi http:\/\/dx.doi.org\/10.16966\/2470-1009.137.","journal-title":"J Drug Res Dev"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfs061"},{"key":"e_1_3_4_26_2","article-title":"Preclinical development of KBP-5074, a novel non-steroidal mineralocorticoid receptor antagonist for the treatment of cardiorenal diseases.","volume":"4","author":"Chow CP","year":"2018","unstructured":"Chow, CP, Liu, JR, Tan, XJ, Yang, F, Huang, ZH. Preclinical development of KBP-5074, a novel non-steroidal mineralocorticoid receptor antagonist for the treatment of cardiorenal diseases. J Drug Res Dev. 2018;4:dx.doi.org\/10.16966\/2470-1009.143.","journal-title":"J Drug Res Dev"},{"key":"e_1_3_4_27_2","volume-title":"Poster presented at American Society of Nephrology Kidney Week meeting","author":"Zhang B","year":"2016","unstructured":"Zhang, B, Tan, X, Ni, S. Pharmacokinetics and safety of KBP-5074 in phase 1 single and multiple ascending dose studies. Poster presented at American Society of Nephrology Kidney Week meeting, 2016."},{"key":"e_1_3_4_28_2","first-page":"931A","article-title":"Safety, tolerability and pharmacokinetics of KBP-5074 in patients with mild-to-moderate chronic kidney disease [abstract PUB116].","volume":"27","author":"Zhang B","year":"2016","unstructured":"Zhang, B, Crawford, PW, Smith, WB, Lasseter, K, Yang, F, Tan, X, Pelka, P. Safety, tolerability and pharmacokinetics of KBP-5074 in patients with mild-to-moderate chronic kidney disease [abstract PUB116]. J Am Soc Nephrol. 2016;27:931A.","journal-title":"J Am Soc Nephrol"},{"key":"e_1_3_4_29_2","volume-title":"Poster presented at the American Society of Nephrology Kidney Week 2017 meeting","author":"Connaire J","unstructured":"Connaire, J, Bush, M, Ruckle, J, Tan, X, Benn, V, Fred Yang, F. Safety, tolerability, and pharmacokinetics of the selective mineralocorticoid receptor antagonist KBP-5074 in hemodialysis and non-hemodialysis patients with severe chronic kidney disease. Poster presented at the American Society of Nephrology Kidney Week 2017 meeting."},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2006.077180"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32135-X"},{"key":"e_1_3_4_32_2","unstructured":"Centers for Disease Control and Prevention. Chronic Kidney Disease Surveillance System\u2014United States. Available at: https:\/\/nccd.cdc.gov\/ckd\/detail.aspx?Qnum=Q8#refreshPosition. Accessed March 24 2020."}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/HYPERTENSIONAHA.120.15199","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T10:43:28Z","timestamp":1715597008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/HYPERTENSIONAHA.120.15199"}},"subtitle":["BLOCK-CKD Trial"],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1161\/HYPERTENSIONAHA.120.15199"],"URL":"https:\/\/doi.org\/10.1161\/hypertensionaha.120.15199","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"2020-04-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}